BriaCell Therapeutics Corp · TSX:BCT

BriaCell Therapeutics — Investor Presentation (July 2016)

24 slides from BriaCell Therapeutics's investor presentation, July 2016

  1. Slide 1: BriaCell Therapeutics Corp.

    BriaCell Therapeutics Corp. OTCQB: BCTXF TSX-V: BCT JULY 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect BriaCell’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause BriaCell’s a

  3. Slide 3: Investment Highlights

    Investment Highlights  Leading Technology: Novel cancer immunotherapy  Right Timing: Initiating a Ph I/IIa clinical trial to validate the impressive safety and efficacy data of the two preliminary Ph I clinical trials  Unique Approach: Companion diagnostic co-development  Significant Market Pote

  4. Slide 4: Cancer Immunotherapy BriaVax (SV-BR-1-GM)

    Cancer Immunotherapy BriaVax™ (SV-BR-1-GM)  Breast cancer cell line  Allogeneic whole-cell vaccine secreting GM-CSF (“GVAX”).  Scalable production - grows as cancer cell line in RPMI + 10% FBS.  Irradiation prior to injection to prevent replication.  Used in combination with cyclophosphamide, a

  5. Slide 5: BriaVax Development Story

    BriaVaxTM Development Story Dr. C. L. Wiseman (left) helped pioneer chemotherapies before they BriaVaxTM is a proprietary were considered a possibility. breast cancer cell vaccine expressing GM-CSF Impressive safety and efficacy data in a , preliminary Phase I clinical trial Planning Phase I/IIa tes

  6. Slide 6: Clinical Data to-date

    Clinical Data to-date First Phase I:  Used unmodified cell line + GM-CSF + cyclophosphamide  N = 14 late stage, treatment-refractory breast cancer patients  No significant adverse events, well tolerated  Median Overall Survival = 12.1 months Second Phase I:  Used GM-CSF-engineered cell line + c

  7. Slide 7: Clinical Data to-date

    Clinical Data to-date Second Phase I (using BriaVaxTM) 1 out of 4 Subjects responded with substantial tumor regression 7

  8. Slide 8: Clinical Data to-date

    Clinical Data to-date Lesion 1 Lesion 2 baseline 3 re-inoculations baseline 3 re-inoculations Lesion 3 baseline 3 re-inoculations 8

  9. Slide 9: Hypothetical Mechanism of Action

    Hypothetical Mechanism of Action  Tumor regression in a patient was directly related to rising levels of CD40 Ligand (CD40L), a protein that is expressed on components of the immune system including activated T cells, B cells, platelets, monocytic cells, natural killer (NK) cells, mast cells, and b

  10. Slide 10: Hypothetical Mechanism of Action

    Hypothetical Mechanism of Action Tumor Regression – Series-I Tumor Re-Regression – Series-II Baseline 3 Vaccines 6 Vaccines 3 Additional Vaccines Relapsed Before Treatment 6 Weeks Treatment 20 Weeks Treatment 8 Weeks CD40L Levels During Treatment CD40L Levels During Re-Treatment Series-I Series-II 4

  11. Slide 11: Hypothetical Mechanism of Action: CTA Analysis

    Hypothetical Mechanism of Action: CTA Analysis  Cancer Testis Antigens (CTAs): A class of cancer tissue specific antigens  PRAME: The CTA expressed in some breast cancers. The PRAME is also expressed in BriaVax™.  BriaVax™ injection may activate the patient T cells by PRAME recognition to cause t

  12. Slide 12: Hypothetical Mechanism of Action: HLA Analysis

    Hypothetical Mechanism of Action: HLA Analysis  BriaVax™ caused a significant tumor shrinkage in one patient (Subject A002) - even at metastatic sites (Wiseman and Kharazi, Breast J 2006).  HLA analysis of BriaVax™ and peripheral blood lymphocytes from the 4 patients showed that the special respon

  13. Slide 13: Hypothetical Mechanism of Action of BriaVax

    Hypothetical Mechanism of Action of BriaVaxTM  BriaVax™ expresses several genes known for their roles in immune cells, including HLA-A and HLA-DRB3.  BriaVax™ may do one or few of the following: A. Directly act as antigen-presenting cells (APCs) B. Cross-Presentation: Dendritic cells may take up d

  14. Slide 14: Discovery of Gene Signature of BriaVax – Implications

    Discovery of Gene Signature of BriaVaxTM – Implications  BriaCell discovered a pair of biomarkers (HLA alleles) present in the top- responder and BriaVaxTM but not in the 3 other clinical trial subjects  Implications: i. It improves our understanding of how the vaccine works, thus improving the li

  15. Slide 15: Phase I/II Open Label Clinical Trial

    Phase I/II Open Label Clinical Trial IND Cleared by FDA in Nov 2015:  Up to 24 stage-IV breast cancer patients  Primary objective: Safety & tumor response  Designed to amend the trial to evaluate: • Extending the dosing schedule (not limited to 6 vaccine injections) • Use in combination with othe

  16. Slide 16: Accelerating the Clinical Development of BriaVax

    Accelerating the Clinical Development of BriaVaxTM BriaVax™ BriaDx™ Combination therapy Companion diagnostics to boost efficacy: co-development Molecular analysis of Allogeneic tumor cell line blood and potentially + tumor samples GM-CSF secretion + Predict BriaVax™ Cyclophosphamide responsiveness +

  17. Slide 17: Targeting a multi-billion dollar market

    Targeting a multi-billion dollar market  FDA has allowed the testing of BriaVaxTM for other cancer indications Annual Potential Market (in Cancer Type Mortality (US) Million $US) at $100K/yr Breast 40,890 $4,089 at $100K/yr Annual Potential Market (in Cancer Type Mortality (US) Million $US) at $100

  18. Slide 18: Upcoming Milestones

    Upcoming Milestones Milestone Expected Timing Completion of manufacturing of BriaVaxTM for Ph I/IIa trial 2H2016 Initiation of Ph I/IIa clinical trials of BriaVaxTM 2H2016 Filing for additional patents 1H2017 Interim Data for Ph I/IIa trial 2H2017 Presentation of clinical data at a major conference

  19. Slide 19: Management and Board

    Management and Board Management Board Rahoul Sharan, CA, CEO & Director Saeid Babaei, PhD, MBA, Chairman  Chairman, Potash Ridge  Entrepreneur. 20 yrs of biotech leadership roles  30 yrs of finance & accounting experience  CEO, AbCelex - Obtained funds from a top agri-tech/biotech VC  Board of

  20. Slide 20: Financials

    Financials Data as of 7/11/2016 Ticker TSX: BCT.V Other Listing OTCQB: BCTXF Shares outstanding (in Millions) 91.30 Market Cap (in Million CAD$ ) 15.98 20

  21. Slide 21: Recent Deal Values

    Recent Deal Values Development stage at the time of the Date Partnership deal Deal size Terms 10/20/2014 NewLink Genetics - Ph I Up to $1.15 Bil Upfront payment of $150 M; Up to $1 Bil payments for certain Genentech milestones ; Escalating double-digit royalties 6/29/2015 Juno Therapeutics/Celgene P

  22. Slide 22: Near-term Plans

    Near-term Plans  Working closely with Cancer Insight, a CRO specializing in cancer immunotherapy, to enroll the first 9 patients.  Analysis of blood samples from the first few patients in the upcoming Phase I/IIa clinical trial to further address the hypothesis that previously identified biomarker

  23. Slide 23: Summary

    Summary  Proprietary vaccine for 2nd line use for advanced breast cancer with potential for 1st line use.  Initiating Phase I/II a to further validate the impressive preliminary Phase I data: • survival was increased by up to 5X • rapid response rate with little side effects  Planning to co-devel

  24. Slide 24: TSX: BCT.V OTCQB: BCTXF [email protected] | 1-888-485-6340 | BriaCell.com

    TSX: BCT.V OTCQB: BCTXF [email protected] | 1-888-485-6340 | BriaCell.com

BriaCell Therapeutics — Investor Presentation (July 2016) on 6ix